Zhang, Ziyang http://orcid.org/0000-0003-0541-7211
Guiley, Keelan Z.
Shokat, Kevan M. http://orcid.org/0000-0001-8590-7741
Funding for this research was provided by:
Samuel Waxman Cancer Research Foundation
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | National Institutes of Health (R01CA244550)
The Emerald Foundation The Mark Foundation
Damon Runyon Cancer Research Foundation (DRG-2281-17, DRG-2399-20)
Article History
Received: 9 April 2022
Accepted: 18 May 2022
First Online: 21 July 2022
Competing interests
: K.M.S. and Z.Z. are inventors of a patent application related to this work owned by University of California. K.M.S. receives stock and/or cash compensation from: Apertor, BioTheryX, BridGene Biosciences, Denali Therapeutics, eFFECTOR Therapeutics, Erasca, G Protein Therapeutics, Genentech/Roche, Ikena, Initial Therapeutics Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Nested, Nextech, Radd Pharma, Revolution Medicines, Turning Point, Type6 Therapeutics, Vevo and Wellspring Biosciences (Araxes Pharma).